Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $2.99 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 72,005 shares of the company’s stock after selling 1,633 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Moderna were worth $2,994,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its position in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Compass Planning Associates Inc bought a new position in Moderna during the fourth quarter worth about $37,000. Larson Financial Group LLC boosted its holdings in Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $34.17 on Tuesday. The company’s 50 day simple moving average is $34.89 and its 200 day simple moving average is $45.39. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The firm has a market capitalization of $13.21 billion, a P/E ratio of -3.68 and a beta of 1.86.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Berenberg Bank raised their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and cut their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Morgan Stanley lowered their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. Finally, Citigroup assumed coverage on shares of Moderna in a report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price objective for the company. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $59.00.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.